ВЕТРЯНАЯ ОСПА И ОПОЯСЫВАЮЩИЙ ЛИШАЙ: ИСТОРИЯ И ПЕРСПЕКТИВЫ ВАКЦИНОПРОФИЛАКТИКИ


Цитировать

Полный текст

Аннотация

Вирус ветряной оспы (VZV) поражает большую часть человечества. На данном этапе представление об иммунитете при VZV-инфекции недостаточно полное. Инфекции, вызванные VZV, характеризуются высокой заболеваемостью, болезненностью и смертностью. В ряде стран после введения профилактики ветряной оспы вакциной, содержащей живой аттенуированный штамм Oка, заболеваемость и другие показатели значительно снизились. Опыт вацинопрофилактики в США показал наибольшую эффективность двукратной схемы вакцинации против ветряной оспы. Для профилактики эндогенной реактивации VZV и развития herpes zoster разработана вакцина на основе того же штамма Ока, способная в ряде случаев предотвратить, а при развитии заболевания снизить тяжесть течения. Также в обзоре представлены данные об исследованиях инактивированной, рекомбинантной субъединичной ДНК-вакцины для профилактики первичной VZV-инфекции и поиске новых путей введения вакцины.

Полный текст

Доступ закрыт

Об авторах

Александра Сергеевна КАЗАНОВА

НИИ вакцин и сывороток им. И.И.Мечникова РАМН, Москва

Email: pendelbus@gmail.com
мл. науч. сотр. лаб. диагностикивирусных инфекций

Вячеслав Федорович ЛАВРОВ

НИИ вакцин и сывороток им. И.И.Мечникова РАМН, Москва

д-р мед. наук, проф., рук. лаб. диагностики вирусных инфекций

Дмитрий Васильевич ДУБОДЕЛОВ

Главный центр санитарно-эпидемиологического надзора внутренних войск МВД России

зав. организационно-методическим отд.

Станислав Николаевич КУЗИН

НИИ вакцин и сывороток им. И.И.Мечникова РАМН, Москва

д-р мед. наук., проф., вед. науч. сотр. лаб. диагностики вирусных инфекций

Список литературы

  1. Zerboni L., Berarducci B., Rajamani J. Varicella-zoster virus glycoprotein E is a critical determinant of virulence in the SCID mouse-human model of neuropathogenesis. J Virol. 2011; 85 (1): 98-111.
  2. Jones L., Black A..P, Malavige G.N. Phenotypic analysis of human CD4+ T cells specific for immediate-early 63 protein of varicella-zoster virus. Eur. J. Immunol. 2007; 37 (12): 3393-3403.
  3. Nagel M.A., Choe A., Traktinskiy I. Varicella-zoster virus transcriptome in latently infected human ganglia. J. Virol. 2011; 85 (5): 2276-2287.
  4. Richard A., Santos J., Padilla A. Antigenic variation of varicella zoster virus Fc receptor gE: loss of a major B cell epitope in the ectodomain. Virology 1998; 249 (1): 21-31.
  5. Haumont M., Jurdan M., Kangro H. Neutralizing antibody responses induced by varicella-zoster virus gE and gB glycoproteins following infection, reactivation or immunization. J. Med. Virol. 1997; 53 (1): 63-68.
  6. Wirgart B.Z., Estrada V., Jackson W. A novel varicella-zoster virus gE mutation discovered in two Swedish isolates. J. Clin. Virol. 2006; 37 (2): 134-136.
  7. Natoli S., Ciotti M., Paba P. A novel mutation of varicella-zoster virus associated to fatal hepatitis. J. Clin. Virol. 2006; 37 (1): 72-74.
  8. Michalik D.E., Steinberg S.P., Larussa P.S. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J. Infect. Dis. 2008; 197 (7): 944-949.
  9. Johnson J.A., Bloch K.C., Dang B.N. Varicella reinfection in a seropositive physician following occupational exposure to localized zoster. Clin. Infect. Dis. 2011; 52 (7): 907-909.
  10. Takahashi M., Asano Y., Kamiya H. Development of varicella vaccine. J. Infect. Dis. 2008; 197 (suppl 2): S41-S44.
  11. Grinfeld E., Ross A., Forster T. Genome-wide reduction in transcriptomal profiles of varicella-zoster virus vaccine strains compared with parental Oka strain using long oligonucleotide microarrays. Virus Genes 2009; 38 (1): 19-29.
  12. Yamanishi K. Molecular analysis of the Oka vaccine strain of varicella-zoster virus. J. Infect. Dis. 2008; 197 (suppl 2): S45-S48.
  13. Kuter B.J., Weibel R.E., Guess H.A. Oka/Merck Varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991; 9: 643- 647.
  14. Seward J.F., Marin M., Vazquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J. Infect. Dis. 2008; 197 (suppl. 2): S82-S89.
  15. Krause P.R., Klinman D.M. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J. Pediatr. 1995; 127: 518-525.
  16. White C.J., Kuter B.J., Hildebrand C.S. et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 1991; 87: 604- 610.
  17. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm. Rep. 1996; 45: 1-36.
  18. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 1999; 48: 1-5.
  19. Rasch G., Hellenbrand W. Germany adds varicella vaccine to the national vaccination programme. Euro Surveill 2004; 8: 1.
  20. Roush S.W., Murphy T.V. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. J.A.M.A. 2007; 298: 2155-2163.
  21. Sharrar R.G., LaRussa P., Galea S.A. The postmarketing safety profile of varicella vaccine. Vaccine 2000; 19 (78): 916-923.
  22. LaRussa P., Steinberg S.P., Shapiro E. Varicella vaccine revisited. Nat. Med. 2000; 6 (12): 1299-1300.
  23. Civen R., Chaves S.S., Jumaan A. The incidence and clinical characteristics of herpes zoster among children and adolescents after implementation of varicella vaccination. Pediatr. Infect. Dis. J. 2009; 28 (11): 954-959.
  24. Marin M., Güris D., Chaves S.S. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2007; 56 (RR-4): 1-40.
  25. Galil K., Fair E., Mountcastle N. Younger age at vaccination may increase risk of varicella vaccine failure. J. Infect. Dis. 2002; 186: 102-105.
  26. Haddad M.B., Hill M.B., Pavia A.T. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002-2003. Pediatrics 2005; 115: 1488-1493.
  27. Terada K., Niizuma T., Yagi Y. Low induction of varicella-zoster virus-specific secretory IgA antibody after vaccination. J. Med. Virol. 2000; 62 (1): 46-51.
  28. White C.J., Kuter B.J., Hildebrand C.S. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics. 199; 87 (5): 604 - 610.
  29. Tsolia M., Gershon A.A., Steinberg S.P. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J. Pediatr. 1990; 116 (2): 184-190.
  30. Prevention of varicella: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 19994; 48: 1-5.
  31. Galea S.A., Sweet A., Beninger P. The safety profile of varicella vaccine: a 10-year review. J. Infect. Dis. 2008; 197 (suppl. 2): S165-S169.
  32. Gershon A.A., Chen J., Davis L. Distribution of latent varicella zoster virus in sensory ganglia and gut after vaccination and wild-type infection: evidence for viremic spread. In: 34th International Herpesvirus Workshop 2009 Ithaca. New York; 2009.
  33. Krause P.R., Klinman D.M. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat. Med. 2000; 6 (4): 451-454.
  34. Hardy I., Gershon A.A., Steinberg S.P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N. Engl. J. Med. 1991; 325 (22): 1545-1550.
  35. Brunell P.A., Argaw T. Chickenpox attributable to a vaccine virus contracted from a vaccinee with zoster. Pediatrics 2000; 106 (2): E28.
  36. Brisson M., Edmunds W.J. Varicella vaccination in England and Wales: cost-utility analysis. Arch. Dis. Child. 2003; 88 (10): 862-869.
  37. Mehta S.K., Cohrs R.J., Forghani B. et al. Stress-induced subclinical reactivation of varicella zoster virus in astronauts. J. Med. Virol. 2004; 72 (1): 174-179.
  38. Patel M.S., Gebremariam A., Davis M.M. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Infec. Control Hosp. Epidemiol. 2008; 29: 1157-1163.
  39. Jardine A., Conaty S.J., Vally H. Herpes zoster in Australia: evidence of increase in incidence in adults attributable to varicella immunization? Epidemiol. Infect. 2011; 139 (5): 658-665.
  40. Oxman M.N., Levin M.J. Vaccination against herpes zoster and postherpetic neuralgia. Shingles Prevention Study Group. J. Infect. Dis. 2008; 197 (suppl. 2): S228-S236.
  41. Macaladad N., Marcano T., Guzman M. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 2007; 25 (11): 2139-2144.
  42. Davies J., Hallworth J.A., McLeish P. Characterization and immunogenicity of a candidate subunit vaccine against varicella-zoster virus. Med. Microbiol. Immunol. 1994; 183 (2): 105-117.
  43. Hayward A.R., Buda K., Levin M.J. Immune response to secondary immunization with live or inactivated VZV vaccine in elderly adults. Viral Immunol. 1994; 7 (1): 31-36.
  44. Gershon A.A. Varicella-zoster virus infections. Pediatr. Rev. 2008; 29 (1): 5-10.
  45. Levin M.J., Ellison M.C., Zerbe G.O. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 2000; 18: 2915-2920.
  46. Redman R.L., Nader S., Zerboni L. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J. Infect. Dis. 1997; 176: 578-585.
  47. Hata A., Asanuma H., Rinki M. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N. Engl. J. Med. 2002; 347 (1): 26-34.
  48. Jacquet A., Haumont M., Massaer M. Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation. Vaccine 2002; 20 (11-12): 1593-1602.
  49. Hasan U.A., Harper D.R., Wren B.W. Immunization with a DNA vaccine expressing a truncated form of varicella zoster virus glycoprotein E. Vaccine 2002; 20 (9-10):1308-1315.
  50. Terada K., Niizuma T., Ogita S. Responses of varicella zoster virus (VZV)-specific immunity in seropositive adults after inhalation of inactivated or live attenuated varicella vaccine. Vaccine 2002; 20 (31-32): 3638-3643.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2011